B&K (HKSE:02396) Beta: N/A (As of Jul. 09, 2026)


HKSE:02396 B&K Corp Ltd HKSE:02396
8 GF Score
Price HK$3.89
! 1 Warning Sign
View Full Analysis

What is B&K Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-09), B&K's Beta is Not available.

B&K  (HKSE:02396) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

B&K Beta Related Terms

B&K Beta Historical Data

* Premium members only.

The historical data trend for B&K's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

B&K Beta Chart

B&K Annual Data
Trend Dec23 Dec24 Dec25
Beta
0.00 0.00 0.00

B&K Quarterly Data
Dec23 Dec24 May25 Sep25 Dec25
Beta 0.00 0.00 0.00 0.00 0.00
HKSE:02396
8GF Score
B&K Corp Ltd HKSE:02396
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

B&K Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

B&K Business Description

Address No. 19 Qinling Road, Xiexin Center, Room 1507, Building 1, Laoshan District, Shandong Province, Qingdao, CHN
B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.
8GF Score

Get the complete analysis for HKSE:02396

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.89
Price